Funding for this research was provided by:
Takeda Pharmaceutical Company
Article History
Received: 15 July 2021
Accepted: 5 November 2021
First Online: 27 November 2021
Change Date: 13 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10157-021-02176-8
Declarations
:
: Honoraria: Shuichi Ito (Alexion pharma and Sanofi Genzyme). Research funding: Shuichi Ito (Japan Blood Product Organization and Teijin Pharma). Employment: Yuya Nishiyama, Kenkichi Sugiura, and Kazuaki Enya (Takeda Pharmaceutical Company Limited).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval numbers: CH28-009, 28-7, 1630301, 201602-1, NW2016102 [covering 13 institutions], 16-03, N2016017, 116-185, 2805, 16-02, 160011, 28-07-02, 201602-2, 201602-3, 17004, 1814, 201602-4, 1-29014A, 290501, 1801; approval number not available for two institutions), the 1964 Helsinki declaration and its later amendments, the Good Clinical Practice (GCP) guidelines, and with International Conference on Harmonisation Harmonised Tripartite Guideline for GCP E6.
: Written, informed consent was received from the patients’ parent or legal guardian (and patients, where possible) before the start of the study.